{{Rsnum
|rsid=2304130
|Gene=ZNF101
|Chromosome=19
|position=19678719
|Orientation=plus
|GMAF=0.1451
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=ZNF101
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 81.4 | 16.8 | 1.8
| HCB | 72.8 | 25.0 | 2.2
| JPT | 78.8 | 20.4 | 0.9
| YRI | 61.9 | 34.7 | 3.4
| ASW | 56.1 | 31.6 | 12.3
| CHB | 72.8 | 25.0 | 2.2
| CHD | 71.6 | 27.5 | 0.9
| GIH | 65.3 | 33.7 | 1.0
| LWK | 62.7 | 30.0 | 7.3
| MEX | 72.4 | 25.9 | 1.7
| MKK | 38.5 | 50.0 | 11.5
| TSI | 87.3 | 11.8 | 1.0
| HapMapRevision=28
}}[http://www.genomeweb.com/issues/news/151152-1.html news] three SNPs that appear to have different effects in men and women [[rs3846662]] [[rs2304130]] [[rs2083637]]

{{PMID Auto GWAS
|PMID=19060911
|Trait=Cholesterol, total
|Title=Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts
|RiskAllele=G
|Pval=2E-15
|OR=0.15
|ORtxt=[NR] SD decrease
|OA=1
}}

{{PharmGKB
|RSID=rs2304130
|Name_s=
|Gene_s=ZNF101
|Feature=
|Evidence=PubMed ID:19060911; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. (Initial Sample Size: 17,797 individuals; Replication Sample Size: NR); (Region: 19p13.11; Reported Gene(s): NCAN; Risk Allele: rs2304130-G); (p-value= 0.000003).This variant is associated with LDL cholesterol.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740216
}}

{{PMID Auto GWAS
|PMID=20864672
|Trait=None
|Title=Genetic Variants Influencing Circulating Lipid Levels and Risk of Coronary Artery Disease
|RiskAllele=G
|Pval=4E-8
|OR=0.07
|ORtxt=[0.04-0.10] unit decrease
|OA=1
}}

{{PharmGKB
|RSID=rs2304130
|Name_s=
|Gene_s=ZNF101
|Feature=
|Evidence=PubMed ID:19060911; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. (Initial Sample Size: 22,562 individuals; Replication Sample Size: NR); (Region: 19p13.11; Reported Gene(s): NCAN; Risk Allele: rs2304130-G); (p-value= 0.000000000000002).This variant is associated with Cholesterol, total.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740196
}}

{{PharmGKB
|RSID=rs2304130
|Name_s=
|Gene_s=ZNF101
|Feature=
|Evidence=PubMed ID:19060911; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. (Initial Sample Size: 17,815 individuals; Replication Sample Size: NR); (Region: 19p13.11; Reported Gene(s): NCAN; Risk Allele: rs2304130-G); (p-value= 0.000003).This variant is associated with Triglycerides.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA164740228
}}

{{PMID Auto
|PMID=22359512
|Title=Genome-Wide Association Study Identifies Novel Loci Associated with Circulating Phospho- and Sphingolipid Concentrations
|OA=1
}}

{{PMID Auto
|PMID=20832063
|Title=Exploring genetic determinants of plasma total cholesterol levels and their predictive value in a longitudinal study.
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2304130
|overall_frequency_n=1242
|overall_frequency_d=10758
|overall_frequency=0.115449
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}